StockNow
Calendar
Log in
U.S. Markets

Eli Lilly (LLY) announced results from a new analysis showing that Zepbound (tirzepatide) 10 mg and 15 mg, a dual GIP and GLP-1 receptor agonist, delivered greater weight loss than Wegovy HD (NOVOB DC) in adults with obesity

StockNow breaking-news AI analysis

Eli Lilly announced analysis results showing Zepbound 10 mg and 15 mg achieved greater weight loss than Wegovy HD in adults with obesity.

2 stocks
LLYEli Lilly & Co.$1,189.39Current priceNVONovo-Nordisk A/S$38.35Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

UKMTO notes of a report in the evening of September 28th; says a vessel was struck by an unknown projectile in the Strait of Hormuz; vessel is underway after a resulting fire was extinguished, with the crew safe.

Geopolitics

US President Trump backs Russia sanctions relief on prisoner release, Atlantic reports; Trump expressed support for the plan a few months ago

FX/Bonds

[MARKET UPDATE] Strength in DXY weighing on EUR and GBP; a move which comes amidst a pick-up in global fixed benchmarks